Litcius/Paper detail

Protection against Reinfection with the Omicron BA.2.75 Subvariant

Hiam Chemaitelly, Patrick Tang, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Mohammad R. Hasan, Houssein H. Ayoub, Heba Altarawneh, Zaina Al Kanaani, Einas Al‐Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al‐Kuwari, Adeel A. Butt, Hamad Eid Al‐Romaihi, Mohamed H. Al‐Thani, Abdullatif Al‐Khal, Roberto Bertollini, Laith J. Abu‐Raddad

2023New England Journal of Medicine51 citationsDOIOpen Access PDF

Abstract

Protection against Reinfection with the Omicron BA.2.75 Subvariant To the Editor: The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) became the predominant sublineage in Qatar by September 10, 2022 (Section S1 and Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). We estimated the effectiveness of previous infection with SARS-CoV-2 in preventing reinfection with BA.2.75 using a test-negative, case-control study design (Section S2). 1

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)VaccinationVirologyAntibodyImmunologyInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies
Protection against Reinfection with the Omicron BA.2.75 Subvariant | Litcius